Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1α in non-small cell lung cancer

Cancer Research

Volumn 66, Issue 1, 2006, Pages 143-150

  Csiki, Ildiko ^a   Yanagisawa, Kiyoshi ^a   Haruki, Nobuhiro ^a   Nadaf, Sorena ^a   Morrow, Jason D ^a   Johnson, David H ^a   Carbone, David P ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; THIOREDOXIN; THIOREDOXIN 1; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPOXIA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEOMICS; SITE DIRECTED MUTAGENESIS; TUMOR GROWTH;

CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CELL LINE, TUMOR; CYCLOOXYGENASE 2; ENZYME INDUCTION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; THIOREDOXIN; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 31544467810     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1357     Document Type: Article

References (40)

1. Zhong H, De Marzo AM, Laughner E, et al. Over-expression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999; 59:5830-5.
2. 2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
3. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
4. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
5. Mazure NM, Brahimi-Horn MC, Berta MA, et al. HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochem Pharmacol 2004;68:971-80.
6. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. Faseb J 1998;12: 1063-73.
7. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
8. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999;5:1001-5.
9. Brabender J, Park J, Metzger R, et al. Prognostic significance of cyclooxygenase 2 mRNA expression in non-small cell lung cancer. Ann Surg 2002;235:440-3.
10. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 1998;58:4997-5001.
11. Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 1997;100:1325-9.
12. Stoehlmacher J, Lenz HJ. Cyclooxygenase-2 inhibitors in colorectal cancer. Semin Oncol 2003;30:10-6.
13. Michiels C, De Leener F, Arnould T, Dieu M, Remacle J. Hypoxia stimulates human endothelial cells to release smooth muscle cell mitogens: role of prostaglandins and bFGF. Exp Cell Res 1994;213:43-54.
14. Schmedtje JF, Jr., Ji YS, Liu WL, DuBois RN, Runge MS. Hypoxia induces cyclooxygenase-2 via the NF-κ p65 transcription factor in human vascular endothelial cells. J Biol Chem 1997;272:601-8.
15. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its α subunit J Biol Chem 1996;271:32253-9.
16. Holmgren A. Thioredoxin and glutaredoxin systems, J Biol Chem 1989;264:13963-6.
17. Ema M, Hirota K, Mimura J, et al. Molecular mechanisms of transcription activation by HLF and HIF1α in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 1999;18:1905-14.
18. Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1α protein expression: Trx-1 over-expression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 2002;62:5089-95.
19. Kakolyris S, Giatromanolaki A, Koukourakis M, et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 2001;7:3087-91.
20. Hopfl G, Ogunshola O, Gassmann M. HIFs and tumors: causes and consequences. Am J Physiol Regul Integr Comp Physiol 2004;286:R608-23.
21. Dery MA, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 2005;37:535-40.
22. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16: 4604-13.
23. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;12: 5447-54.
24. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor lot in vascular smooth muscle cells. J Biol Chem 2000;275:26765-71.
25. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003;362:433-9.
26. Welsh SJ, Williams RR, Birmingham A, et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation. Mol Cancer Ther 2003;2:235-43.
27. Harris AL. Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
28. Semenza GL. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol 2000;59:47-53.
29. Semenza GL. Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 2002;41:79-83.
30. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18563-9.
31. 2 is mediated by hypoxia-inducible factor 1. Cancer Res 2003;63:2330-4.
32. Xu Q, Ji YS, Schmedtje JF, Jr. Sp1 increases expression of cyclooxygenase-2 in hypoxic vascular endothelium. Implications for the mechanisms of aortic aneurysm and heart failure. J Biol Chem 2000;275:24583-9.
33. Ji YS, Xu Q, Schmedtje JF, Jr. Hypoxia induces high-mobility-group protein I(Y) and transcription of the cyclooxygenase-2 gene in human vascular endothelium. Circ Res 1998;83:295-304.
34. Yang X, Sheares KK, Davie N, et al. Hypoxic induction of cox-2 regulates proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 2002;27:688-96.
35. Lee PJ, Jiang BH, Chin BY, et al. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 1997;272:5375-81.
36. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-6.
37. Dixon DA, Balch GC, Kedersha N, et al. Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1. J Exp Med 2003;198:475-81.
38. Dixon DA, Tolley ND, King PH, et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 2001;108:1657-65.
39. Bonazzi A, Mastyugin V, Mieyal PA, Dunn MW, Laniado-Schwartzman M. Regulation of cyclooxygenase-2 by hypoxia and peroxisome proliferators in the corneal epithelium. J Biol Chem 2000;275:2837-44.
40. Manalo DJ, Rowan A, Lavoie T, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005;105:659-69.